9MW3811

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug Name9MW3811
Drug Alias Name9MW3811
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-11 inhibitors
TargetsInterleukin-11
Therapy Area/IndicationsSolid tumoursCicatrixFibrosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Langrun Maiwei Biomedical Technology Co LtdCalico Life Sciences LlcMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCicatrixFibrosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A